UPPLUS
LIVE

Serial Number

79298631

Owner

APEX BIOTECH RESEARCH PTY LTD

Attorney

Katherine P. Califa

Filing Date

Oct 21, 2020

Add to watchlist:

No watchlists yet
View on USPTO

UPPLUS Trademark

Serial Number: 79298631 • Registration: 6648775

UPPLUS is a trademark filed by APEX BIOTECH RESEARCH PTY LTD on October 21, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

APEX BIOTECH RESEARCH PTY LTD (3 trademarks)

PO Box 649

Entity Type: 99

Trademark Details

Filing Date

October 21, 2020

Registration Date

February 22, 2022

Published for Opposition

December 7, 2021

Goods & Services

Nutritionally fortified herbal beverages for medicinal use; Nutritionally fortified medicated beverages; Nutritionally fortified medicinal beverages for medical purposes; Vitamin enriched sparkling water for medical purposes; Nutritionally fortified water for medical purposes; Vitamin enriched water for medical purposes; disinfectants for hygiene purposes; Medicated products for oral hygiene, namely, medicated toothpaste; Medicated mouthwash for oral hygiene purposes; Preparations for oral hygiene, namely, medicated toothpaste, other than dentifrices; Preparations for personal hygiene, namely, disinfectants; Disinfectants for hygienic purposes; Acne treatment preparations in the form of cleansers; Acne treatment preparations in the form of creams; anti-bacterial pharmaceutical preparations; Chemical products for pharmaceutical use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Chemicals for pharmaceutical use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations for animals for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Pharmaceutical preparations for application to the skin for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for health care for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for human use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for nasal use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for oral use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for personal use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for topical use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations for veterinary use for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations in the form of emulsions for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical preparations in the form of throat lozenges and medicated lozenges; pharmaceutical preparations in the form of tablets for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical products for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical products derived from natural sources for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; pharmaceutical tonic preparations for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; plant extracts for pharmaceutical purposes; plant extracts for pharmaceutical use; Pharmaceutical preparations in the nature of plant extracts for pharmaceutical use; propolis for pharmaceutical purposes; Drug delivery agents in the form of tablets that facilitate the delivery of pharmaceutical preparations; medicated mouth spray; mouth sprays for medical use; Anti-inflammatory sprays for the body for medical use; sprays for use on the body namely, medicaments for anti-aging, for the treatment and prevention of respiratory illnesses, diabetes, neuro-degeneration, and central nervous system disorders, and for the maintenance, support, and improvement of brain health; Acne treatment sprays for use on the body; medicated mouthwashes; medicated antiseptic mouthwashes; medical mouthwashes; mouthwashes and gargles for medical purposes; mouthwashes for medical purposes; eye drops; throat lozenges for pharmaceutical purposes; medicated throat lozenges; medical toothpastes; medicated toothpaste

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 16, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 27, 2022 FICS
FINAL DISPOSITION PROCESSED
Jul 27, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 22, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
Feb 22, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 7, 2021 NPUB
PUBLISHED FOR OPPOSITION
Dec 7, 2021 PUBO
NOTIFICATION PROCESSED BY IB
Dec 6, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 17, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 17, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 17, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 1, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 1, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 1, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 1, 2021 TROA
REFUSAL PROCESSED BY IB
Apr 25, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 5, 2021 RFCS
REFUSAL PROCESSED BY MPU
Apr 5, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 29, 2021 RFCR
NON-FINAL ACTION WRITTEN
Mar 28, 2021 CNRT
ASSIGNED TO EXAMINER
Mar 22, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 8, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 2, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 26, 2020 REPR